Bioequivalence Study of Different Aprocitentan Tablet Formulations

NCT ID: NCT05196399

Last Updated: 2022-11-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-02-02
• Study Completion Date: 2022-04-07

Brief Summary

The main purpose is to study the pharmacokinetics of aprocitentan (ACT-132577) using 2 different tablet formulations. The clinical pharmacology data will be used to determine bioequivalence of 2 different tablet formulations.

Conditions

Healthy Subjects

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Aprocitentan (reference product)

25 mg film-coated tablet

Group Type: EXPERIMENTAL

Aprocitentan (Formulation A)

Intervention Type: DRUG

A single oral dose of 25 mg.

Aprocitentan (test product)

25 mg film-coated tablet

Group Type: EXPERIMENTAL

Aprocitentan (Formulation B)

Intervention Type: DRUG

A single oral dose of 25 mg.

Interventions

Aprocitentan (Formulation A)

A single oral dose of 25 mg.

Intervention Type: DRUG

Aprocitentan (Formulation B)

A single oral dose of 25 mg.

Intervention Type: DRUG

Other Intervention Names

ACT-132577; ACT-132577

Eligibility Criteria

Inclusion Criteria

• Signed informed consent in a language understandable to the participant prior to any study-mandated procedure.
• Healthy male or female participant aged between 18 and 55 years (inclusive) at Screening.
• Body Mass Index of 18.0 to 30.0 kg/m2 (inclusive) at Screening.
• Systolic blood pressure (SBP) 100-140 mmHg, Diastolic blood pressure (DBP) 60-90 mmHg, and pulse rate 60-100 bpm (inclusive), measured on the dominant arm, after 5 min in the supine position at Screening and on Day 1 pre-dose of the first period.
• Woman of Childbearing Potential who has a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1 of the first period. She must agree to consistently and correctly use (from Screening, during the entire study, and for at least 30 days after the last study treatment administration) a highly effective method of contraception with a failure rate of less than 1% per year.
• Woman of non-childbearing potential, i.e., postmenopausal (defined as 12 consecutive months with no menses without an alternative medical cause; in addition, an FSH test must be performed at Screening to further support postmenopausal status), with previous bilateral salpingectomy, bilateral salpingo oophorectomy or hysterectomy, or with premature ovarian failure (confirmed by a specialist), XY genotype, uterine agenesis.

Exclusion Criteria

• Pregnant or lactating woman.
• Previous administration of aprocitentan.
• Known hypersensitivity to endothelin receptor antagonists or to excipients used in any of the formulations.
• History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatments (appendectomy and herniotomy allowed, cholecystectomy not allowed).
• Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the evaluation of the study results.
• Clinically relevant findings on the physical examination at Screening and on Day -1 of the first period.
• Clinically relevant findings in clinical laboratory tests (hematology and clinical chemistry) at Screening and on Day -1 of the first period.
• Previous treatment with any prescribed medications (including vaccines) or over-the-counter medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 3 weeks or 5 terminal elimination half-lives (t½; whichever is longer) prior to first study treatment administration.
• Legal incapacity or limited legal capacity at Screening.
• Positive COVID-19 test, if performed (subject to current epidemiological regulations in the Czech Republic) during the screening period.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Idorsia Pharmaceuticals Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Idorsia Pharmaceuticals Ltd.

Locations

CEPHA s.r.o.

Pilsen, , Czechia

Countries

Czechia

Other Identifiers

2021-005090-11

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ID-080-110

Identifier Type: -

Identifier Source: org_study_id